In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector

Executive Summary

The rapidly evolving stem cell space may have matured to the level where a single company's misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following the mixed results of Osiris Therapeutics' Prochymal stem cell therapy in an interim look at a study in chronic obstructive pulmonary disease.

You may also be interested in...



iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform

Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.

UK MHRA Explains Procedures For On-Site Inspections In COVID-19 Context

New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.

Nidda Sets Price For Stada Squeeze-Out

Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1129788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel